Skip to content
    HRTX
    Earnings call· Jun 2026(Q2 FY26)

    HERON THERAPEUTICS, INC. /DE/ Q2 FY26 earnings call HRTX

    Aug 10, 2026 Source

    Executive summary

    Heron Therapeutics Q2 FY26 — Mixed Commercial Performance and Strategic Review

    Heron Therapeutics reported mixed Q2 FY26 results, with acute care products Zynrelef and Aponvy showing growth, though overall revenue fell short of internal targets. The company is actively responding to a recent court decision impacting Sinvanti's patent outlook, which has prompted a balance sheet reset, tightened spending, and a formal review of strategic alternatives. Management has withdrawn its full-year guidance due to the increased market uncertainties surrounding potential generic entry and ongoing strategic considerations.

    Highlights

    4

    • Acute care franchise revenue grew 44% year-over-year.

    • Zynrelef net sales increased 9% quarter-over-quarter to $11.1 million, with average daily units growing 19% year-over-year.

    • Aponvy net sales grew 26% quarter-over-quarter to $4.2 million, representing a 74% year-over-year increase, and reached 23% share of the surgical NK1 segment.

    • Adjusted EBITDA was $3.2 million, up from $2.2 million in the comparable prior year quarter.

    Concerns

    5

    • Net revenue for the quarter was $37.7 million, which was below internal expectations.

    • Zynrelef and Sinvanti sales were slower than anticipated.

    • The company reported a net loss of $5.5 million, compared to a net loss of $2.4 million in the comparable prior year quarter.

    • Full-year 2026 guidance for net product sales ($173 million to $183 million) and adjusted EBITDA ($10 million to $20 million) was withdrawn.

    • A US District Court decision regarding certain patents covering Sinvanti led to a balance sheet reset and preparation for potential generic competition.

    Guidance & targets

    3
    CategoryTargetConfidence
    Full-year 2026 Net Product Sales
    Withdrawn
    high materiality
    Low
    Full-year 2026 Adjusted EBITDA
    Withdrawn
    high materiality
    Low
    Debt Covenants
    Reset through 2027
    high materiality
    High

    Segment performance

    6
    SegmentRevenueYoYQoQMargin
    Acute Care Franchise
    Combined revenue for Zynrelef and Aponvy.
    		$15.3M44%——
    Zynrelef
    Net sales were up from $10.2 million in Q1. Unit growth was real but below planned rate, focusing on converting access into cases and protocols.
    Average daily units: up 19% year-over-yearIgnite 2.0 active accounts: 3,150
    		$11.1M35%9%—
    Aponvy
    Net sales were up from $3.4 million in Q1. P&T approvals represent 6.7 million medium to high-risk procedures annually.
    Share of surgical NK1 segment: 23%Share of surgical NK1 segment sequential change: up 2 pointsAverage daily units: up 59% year-over-yearOrdering accounts in June: up 42% from June of last yearP&T approvals: 1,810 accounts
    		$4.2M74%26%—
    Oncology Franchise
    Combined revenue for Sinvanti and Sustol.
    		$22.3M———
    Sinvanti
    Net sales were up from $20.5 million in Q1. Year-over-year decline due to branded competition. Utilization and share have held steady in recent months, in line with 12-month average.
    Share: 25%Ordering accounts in June: 1,241
    		$21.8Mdown 10%——
    Sustol
    Continuing planned wind down.
    		$0.5M———

    Operational metrics

    13
    Gross margin
    69.3%
    Q2 FY26
    R&D expense
    $2.7M
    Q2 FY26
    SG&A expense
    $25.4M
    Q2 FY26
    Total operating expenses
    $28.1M
    Q2 FY26
    Operating loss
    $2M
    Q2 FY26
    Net loss
    $5.5Mvs $2.4M prior year quarter
    Q2 FY26
    Adjusted EBITDA
    $3.2Mup from $2.2M prior year quarter
    Q2 FY26
    Cash, cash equivalents, and short-term investments
    $42.7M
    Q2 FY26
    Pro forma cash after principal reduction
    $28.5M
    Q2 FY26

    Reflects $13.5 million principal reduction paid at amendment's execution.

    Pro forma cash after principal reduction (potential)
    $24.3M
    Q2 FY26

    Reflects potential additional $4 million reduction scheduled on or before September 15th.

    Principal reduction
    $13.5M
    Q2 FY26

    Part of the amended credit facility with Hercules.

    Potential additional principal reduction
    $4M
    Q3 FY26

    Part of the amended credit facility with Hercules, for a total potential reduction of $17.5 million.

    Sinvanti annual units
    750,000-800,000
    annual

    Referenced by management when discussing the scale a generic competitor would need to meet market demand.

    Industry KPIs

    4
    MetricValueDetails
    Launch access metrics1,810accounts
    Product franchise net sales$21.8MUSD
    Therapeutic drug market share23%%
    Prescription volume new starts19%%

    Deals & partnerships

    1
    HerculesAmendment to credit facilitythrough 2027

    The amendment waives June 30th covenants and sets monthly minimum revenue, EBITDA, and cash covenants through December 2027. Filed with the 10-Q.

    Risks & headwinds

    4
    Sinvanti generic competitionNear-term to medium-term

    Potential entry of generic product; 750,000-800,000 units/year market size

    Mitigation: Filed appeal against court decision; defense strategy built on clinical profile, customer relationships, and contracting position; noted potential manufacturing and reimbursement challenges for generics.

    Below-expectation sales performanceQ2 FY26

    Q2 FY26 net revenue of $37.7M was below expectations; Zynrelef and Sinvanti sales slower than anticipated.

    Mitigation: Focusing on execution to convert access into cases and protocols for Zynrelef; defense of contracting and formulary work for Sinvanti.

    Withdrawal of full-year guidanceFY26

    Withdrawal of FY26 net product sales guidance ($173M-$183M) and adjusted EBITDA guidance ($10M-$20M).

    Mitigation: Decision made due to uncertainty from court decision, paused salesforce expansion, and strategic alternatives review; will report cash position, spending, and covenant compliance quarterly instead.

    Macro volatility impacting surgical volumesQ2 FY26

    Competitors reported macro volatility impacting healthcare spending, potentially affecting Zynrelef.

    Mitigation: Management believes they were not as impacted due to continued P&T wins, but acknowledged slower pull-through on some initiatives, expecting them to materialize in H2.

    What to watch in Q3 FY26

    4

    Sinvanti generic launch timing and impact

    Next quarter / H2 FY26
    CurrentGeneric has not launched
    TargetClarity on launch timing, terms, and market impact

    Why it matters

    The timing and terms of generic entry for Sinvanti, the company's largest product, will significantly impact revenue and profitability.

    First, the June court decision. The timing and terms of potential generic entry against Cervantes, our largest product, are not events we can forecast, and any annual number would embed an assumption we are not in a position to make.

    Q&A highlights

    4

    Can management elaborate on confidence in meeting updated debt covenants if a Sinvanti generic launches, and whether generic erosion would resemble Sustol's curve?

    Management took a very conservative approach with Hercules on the covenants, modeling an early generic launch. They believe the actual generic launch could be delayed due to manufacturing challenges (sterile process, emulsion, scaling 750k-800k units/year) and reimbursement complexities (J code). This conservative modeling provides comfort regarding covenant compliance.

    “The way we looked at Cervantes, again, we took a very conservative approach with how we looked at the generic launch. In reality, there's a number of factors here that are at play. First of all, we don't know when the product does come to market. know that there's some manufacturing challenges with this product as we go through them ourselves. It's a sterile process. It's an emulsion.”

    asked by Brandon Fulks · answered by Craig Collard

    2 min read4 chapters

    Detailed Narrative

    01

    Balance Sheet Reset and Spending Tightening

    Following the June court decision regarding Sinvanti patents, Heron Therapeutics amended its credit facility with Hercules. This amendment resets debt covenants through 2027 to align with the company's revised operating plan and includes a principal reduction. The company paused its planned salesforce expansion for the second half of the year and is holding spending tightly while the competitive landscape for Sinvanti clarifies. These decisions reflect a responsive approach to business conditions rather than adherence to an outdated plan.

    02

    Sinvanti Patent Defense and Generic Preparedness

    Heron has filed an appeal against the June court decision concerning certain Sinvanti patents. While a generic has not yet launched, the company is actively preparing for potential generic competition. The defense strategy is built around Sinvanti's clinical profile, existing customer relationships, and contracting position, with execution underway to preemptively address market changes. Management noted potential manufacturing and reimbursement challenges for any generic entrant, which could delay market entry or impact share.

    03

    Strategic Alternatives Under Consideration

    The company is exploring strategic alternatives while continuing to execute its current business plan. There is no set timetable for this process, and no assurances can be given that it will result in any transaction. Heron does not intend to provide further comments on this matter unless additional disclosure is deemed appropriate or legally required. This review is one of the factors contributing to the withdrawal of full-year guidance.

    04

    Acute Care Performance and Market Share Gains

    The acute care franchise demonstrated strong year-over-year revenue growth of 44%. Zynrelef net sales grew 9% quarter-over-quarter and 35% year-over-year, with average daily units increasing 19% year-over-year, reaching 3,150 active accounts for Ignite 2.0. Aponvy also showed significant growth, with net sales up 26% quarter-over-quarter and 74% year-over-year, capturing 23% share of the surgical NK1 segment and securing 1,810 P&T approvals. Despite growth, both products performed below internal expectations for the quarter.

    AI-generated summary of the company’s earnings call. Not investment advice.